Skip to content

Study · Non-randomized trial · 2019

3 results

Development and application of a high-throughput liquid chromatography-tandem mass spectrometric method for the simultaneous determination of thymosin α1 and its recombinant human form in plasma and urine.

Wang T, Yin L, Wang H, Fawcett JP, Gu J

Journal of pharmaceutical and biomedical analysis15 Mar 2019Cited by 1 (Europe PMC)

PMID30903925 (opens in a new tab)DOI10.1016/j.jpba.2019.03.030 (opens in a new tab)PepBankPUB-30903925
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy male volunteers given single subcutaneous injections, Tα1 was not deacetylated to recombinant rh-Tα1 in vivo.

    In plain wordsIn healthy men given one injection, natural-form thymosin alpha‑1 was not converted to the recombinant form in the body.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeDeacetylation of Tα1 to rh-Tα1 in vivo
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The results indicate that rh-Tα1 undergoes NTA in vivo to form Tα1 but that Tα1 is not deacetylated to rh-Tα1.
    1 context sentence
    Summary · context
    The method was successfully applied to a comparative pharmacokinetic study involving single subcutaneous injections of either Tα1 or rh-Tα1 to two groups of healthy male volunteers.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialPharmacokinetics

    In healthy male volunteers given single subcutaneous injections, recombinant human Tα1 (rh-Tα1) underwent N-terminal acetylation in vivo to form Tα1.

    In plain wordsIn healthy men given one injection, the recombinant form of thymosin alpha‑1 was converted in the body into the natural form.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableN-terminal acetylation of rh-Tα1 to Tα1 in vivo
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The results indicate that rh-Tα1 undergoes NTA in vivo to form Tα1 but that Tα1 is not deacetylated to rh-Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03LabNot a test of Thymosin alpha-1 aloneOther designOther

    An LC-MS/MS bioassay measured Tα1 and rh-Tα1 in human plasma and urine over a linear range of 2-100 ng/mL.

    In plain wordsIn lab tests, a mass spectrometry method measured both forms of thymosin alpha‑1 in plasma and urine from 2 to 100 ng/mL.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableLC-MS/MS assay linear range for Tα1 and rh-Tα1
    Study

    humann: not reported in source

    human plasma and urine
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Linear range
    2 to 100 ng/mL
    Tα1 and rh-Tα1 in human plasma and urine

    Source sentences

    Summary
    The method was linear in the range 2-100 ng/mL for both analytes with good accuracy and precision.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.